VS3 Medical Announces First Patients Enrolled in First-in-Human Study of Novel Neurovascular Implant to Address Symptomatic Venous Sinus Stenosis
VS3 Medical, Inc., a private company developing novel neurovascular implants, today announced it has commenced enrollment in its international first-in-human (FIH) study evaluating its VS3 Medical™ Stent System for patients with symptomatic venous sinus stenosis. Symptomatic venous sinus stenosis is characterized by narrowing of the brain’s main drainage veins. The first cases enrolled were presented at the 2026 Society of Neuroinventional Surgery (SNIS) Cerebral Venous and CSF Disorders Summit, held March 5-7, 2026, in Colorado Springs, Colo.
